This document discusses hypertension in pregnancy and preeclampsia. It begins by defining hypertension and preeclampsia and discussing their incidence and complications. It then covers prediction and prevention of preeclampsia, including optimal aspirin dosage and timing. The document recommends tight blood pressure control and lists antihypertensive agents. It provides guidance on managing severe hypertension, including intravenous drugs and magnesium sulfate administration. Throughout, it compares guidelines from ISSHP 2018, NICE 2010, and other sources.
Lecture by Dr Sujoy Dasgupta in BOGSCON 2015, the Annual Conference of Bengal Obstetric and Gynaecological Society, held at Hotel Novotel, Kolkata in January, 2015; where he had been invited as FACULTY to deliver his lecture
Identifying women with GDM is important because appropriate therapy can decrease maternal and fetal morbidity .
Can prevent two generations from developing diabetes in the future.
Lecture by Dr Sujoy Dasgupta in BOGSCON 2015, the Annual Conference of Bengal Obstetric and Gynaecological Society, held at Hotel Novotel, Kolkata in January, 2015; where he had been invited as FACULTY to deliver his lecture
Identifying women with GDM is important because appropriate therapy can decrease maternal and fetal morbidity .
Can prevent two generations from developing diabetes in the future.
AUB in ADOLESCENTS Dr. Jyoti Bhaskar Dr. Sharda Jain Dr. Jyoti AgarwalLifecare Centre
PREVALENCE
A population based study of 1000 adolescents:
Incidence of AUB is 40%
Out of those who have AUB
20% have bleeding disorders
Von Willebrand disease, 5%-36%;
Platelet function defects, 2%-44%;
Thrombocytopenia, 13%- 20%
Clotting factor deficiencies, 8%-9%.
AUB in ADOLESCENTS Dr. Jyoti Bhaskar Dr. Sharda Jain Dr. Jyoti AgarwalLifecare Centre
PREVALENCE
A population based study of 1000 adolescents:
Incidence of AUB is 40%
Out of those who have AUB
20% have bleeding disorders
Von Willebrand disease, 5%-36%;
Platelet function defects, 2%-44%;
Thrombocytopenia, 13%- 20%
Clotting factor deficiencies, 8%-9%.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
3. Definition of hypertension in pregnancy
Classification of hypertensive disease in pregnancy
Definition of preeclampsia
Prediction and prevention of PE
Optimal dosage and timing of aspirin
Management of non-severe and severe hypertension in pregnancy
4.
5.
6. Incidence of hypertension in pregnancy is 2.69 – 3.14% (? Underreporting as
most commonly cite incidence of hypertension in pregnancy 5 – 10%)
Of which gestational hypertension accounts for 60 – 70% of cases
Fetal complications
prematurity – 7.6 – 11.7%
IUGR – 12 – 15%
FSB – 6 – 8%
MSB – 7 – 11%
Maternal complications
Abruptio placenta
PE
PPH
DIVC
APO
Maternal collapse
7.
8. Previously – Training manual on hypertension in pregnancy 2014
4 – 6 hours apart
13. White coat hypertension
Should not be
considered as low risk as
there is 50% risk of GH
and 8% risk of PE
Since we do not have facility
for ABPM, any BP reading
≥140/90 in early pregnancy
even though only single
reading require monitoring.
Transient hypertension at
any gestation has 20%
chance of PE and another
20% of gestational
hypertension
16. Proteinuria Is No Longer Required To Diagnose
Pre-eclampsia; It’s present in 75% of the case
Others:
Pulmonary Oedema
Placenta Abruption
Oliguria
Epigastric /RHC Pain
17. The term ‘severe preeclampsia’ should
not be used in clinical practice
• PE may become a major threat at any
stage
• Classification into mild or severe
may be misleading/falsely reassuring
• ACOG has eliminated the diagnosis
of severe PE
• ISSHP recommends clinical
approach of PE with/without severe
features (as detailed in the table)
19. If proteinuria is diagnosed but subsequent dipstick test are negative,
further quantification tests are appropriate to see whether or not true
proteinuria persists
Gestational proteinuria
New onset of proteinuria in pregnancy without other obvious features of PE
or primary renal disease
3 possible outcomes
No features of PE and proteinuria disappears postpartum
Proteinuria turns out to be first sign of PE
Proteinuria persists postpartum and signifies renal disease
Recommended to monitor these patient more closely and assess proteinuria 3
months postpartum
20. ISSHP 2018 stated the following for prediction of PE
No 1st or 2nd trimester test or set of test can reliably predict the development
of all cases of PE
Combination of maternal risk factors, BP, PIGF and uterine artery doppler
can select women who may benefit from aspirin
Supports first trimester screening for PE although the cost effectiveness of
this approach remains to be established
ISSHP 2018 recommends
Women with established strong clinical risk factors for preeclampsia to be
treated with aspirin, ideally before 16 weeks but DEFINITELY before 20 weeks
23. Research questions
Who – will benefit most from aspirin
What – is optimal dosage of aspirin
When to start aspirin
When to take aspirin
24. Aspirin is more effective in high risk women
NNT 19 compared with women at moderate risk (NNT 119)
What constitute high risk women
On the basis of risk factors (as being used in NICE) – poor performance with
detection rate of preterm PE of 39% at a FPR of 10%
ISSHP 2018 recommends
Combination of maternal risk factors, BP, PIGF and uterine artery doppler can select
women who may benefit from aspirin
Based on ASPRE study
Cost effectiveness unknown
25. Aspirin is more effective at higher dose
1/3 of pregnant women are both resistant to the effects of 75 – 80 mg of
aspirin
ISSHP 2018 and Malaysian CPG on Management of hypertension 2018
Aspirin should be give at a dose of 100 – 150 mg/day
Based on ASPRE study that demonstrated the use of 150 mg/day aspirin at
night reduced the incidence of preterm PE from 4.3% to 1.6% in aspirin group
26. Aspirin is more effective when it is started before 16 weeks
ISSHP 2018
Aspirin to be started before 16 weeks and definitely before 20 weeks
Possibly taken at night based on ASPRE study
27. ISSHP 2018 (concurred with Malaysian CPG on Management of
hypertension)
Calcium at the dose of at least 1g/day – reduce the likelihood of PE in women
with low calcium intake
CAP trial – will further examine preventive benefits of calcium supplementation in
calcium-replete women
Exercise (aerobic exercise for 50 min, 3x per week) – associated with reduced
gestational hypertension and PE
Vitamin C and E are not recommended – increase the incidence of low birth
weight
The role of Vitamin D is not proven
28. MODERATE RISK
(any TWO of the following)
1. Primigravida
2. 40 year-old and above
3. Pregnancy interval > 10 years
4. BMI > 30 at booking
5. Family history of pre-eclampsia
6. Multiple pregnancy
HIGH RISK
(any ONE of the following)
1.Hypertensive disease in previous pregnancy.
2.Chronic renal disease
3. Autoimmune disease such as SLE and APS
4. Chronic hypertension
5. Type 1 or 2 DM
Assessment at booking.
Identifying risk factor
for Pre-eclampsia
Start T. aspirin 100 – 150 mg OD after 12 weeks. Preferably
before 16/52 but definitely before 20 weeks; taken at night
Start T. calcium carbonate 1g bd from 20 weeks.
May be still beneficial if started from up to 34 weeks.
29. Start treatment when BP ≥
150/100 regardless of type of
hypertension in pregnancy
Target BP < 150/80 – 100
NICE 2010
Start treatment when BP ≥
140/90 regardless of type of
hypertension in pregnancy
Target BP < 160/85
(According to CHIPS trial)
Antihypertensive should be
reduced if DBP < 80
ISSHP 2018
31. CHIPS Trial
Control of Hypertension In Pregnancy Study
Compare outcome of less-tight control (target DBP 100 mmHg) and tight
control (target DBP 85 mmHg)
987 women; 75% had pre-existing hypertension; 25% with gestational
hypertension; 50% developed PE
Similar primary outcome – pregnancy loss or high-level neonatal care
Severe hypertension (≥ 160/110) developed in 40.6% of women in the less-tight
control group vs 27.5% in tight-control group (p<0.001)
Acceptable oral antihypertensive: labetalol, methyldopa, nifedipine;
prazocin and hydralazine as second and third line
32. Antihypertensive
agents
Dosage Remarks
Methyldopa 250 – 500 mg twice daily – four times/day
(max dosage – 3000 mg/day; however in view of
potential side effects with higher dose, it is advisable to
give a total dose of 2000 mg/day).
Potential side effects include
depression, hepatitis, positive direct
Coombs test
Labetalol 100 – 400 mg twice daily to four times/day
(usual dose 1200 mg/day; max dose 2400 mg/day)
*in cases where BP is uncontrolled with usual dose of
1200mg/day, discussion should be made with specialist
to increase the dose to max of 2400mg/day
Contraindicated in women with
bronchial asthma, congestive cardiac
failure or heart block
Nifedipine 10 mg three times daily
(max dose is 60 mg/day)
*in cases where BP is uncontrolled with usual dose of 10
mg 3 times daily,, discussion should be made with
specialist to increase the dose to max of 60mg/day
Side effects include maternal
hypotension, tachycardia and
headache
33. BP monitoring (HBPM as adjunct to monitoring in clinic)
Monitor for Preeclampsia – urinalysis every visit
Fetal monitoring – serial ultrasound from 26 weeks onwards; at 4 weeks
interval or 2 weeks interval if there is growth abnormality
Timing of delivery depends on types of hypertension in pregnancy,
maternal or fetal compromise
34. SBP ≥ 160 or DBP ≥ 110; surrogate marker for the risk of stroke; reflection of
increased severity of the overall condition of PE; associated with adverse
outcome for both mother and baby
MAP is not part of definition of severe hypertension – no clinical studies to
relate MAP levels to risk and outcome
General principles of management of severe hypertension:
Control of blood pressure
Prevention/control of eclampsia
Maternal and fetal monitoring
Fluid management
Delivery
35. The major considerations in controlling blood:
Oral Nifedipine and parenteral Labetalol are the agents of choice when
BP is 160/110 mmHg as both are equally effective.
However, when systolic blood pressure is 180 mmHg, it is a medical emergency in
which blood pressure should be controlled more rapidly with parenteral
antihypertensive agents.
Parenteral hydralazine is an option when labetolol is contraindicated or fails to control
BP.
Intravenous Glyceryl trinitrate (GTN) can be considered in case of resistant
hypertension.
36. The goal of blood pressure control - non-severe level instead of
normalization of blood pressure.
Therefore, target BP should be 140 – 159/90 – 109 mmHg.
Overzealous control of BP should be avoided as to avoid maternal
hypotension and thus, causing compromise in uteroplacental
perfusion.
Close fetal monitoring is recommended while trying to control the BP.
continuous CTG monitoring or if the gestation is less than 28 weeks, fetal
heart rate should be checked at 5 – 10 minutes interval with daptone.
Algorithm of BP control in severe hypertension
37. 1 vial IV Labetalol contains 25mg/5mls
(1ml = 5 mg IV Labetalol)
Side effects of IV labetalol
Maternal bradycardia
Fetal bradycardia
Contraindications of IV labetalol
Bronchial asthma
Congestive heart failure
Heart block
38. Bolus dose IV Labetalol
Indications BP 160/110 mmHg
Preparation Dilution is not necessary; Use pure form with concentration of 5 mg/ml
Bolus dose (s) 1st dose – 25 mg (5 ml); given in 2 minutes
2nd dose – 50 mg; given in 2 minutes if BP is 160/110 mmHg 30 minutes after
the 1st bolus
*3rd dose – 50 mg may be given if SBP is 180 mmHg 30 minutes after the 2nd
bolus and rapid BP controlled is desired
*In hypertensive emergency (SBP 180 mmHg) or in situation where rapid BP controlled is desired,
3rd bolus dose of intravenous labetalol may be given at the discretion of managing specialist.
39. Infusion
dose
IV Labetalol
Indication BP 160/110 mmHg after 2 or 3 boluses of intravenous labetalol
Preparation Dilution is not necessary
Withdraw 10 vials (total of 250 mg) into 50 cc syringe
Titration Starting dose is 20 mg/H (4 ml/H)
Titration should be done every 30 minutes to achieve target BP
Titration of dose:
o 20 mg/H (4 ml/H) 40 mg/H (8 ml/H) 80 mg/H (16 ml/H) 160
mg/H (32 ml/H)
Target BP: 140 – 150/90 – 109 mmHg
Maintain the dose if target BP is achieved
Titrate down the dose if BP is < target BP
40. 1 vial IV hydralazine contains
20mg/1 ml
Side effects of IV Hydralazine
maternal hypotension
maternal tachycardia
headache and dizziness
41. Bolus dose IV Hydralazine
Indications BP 160/110 mmHg when parenteral Labetalol is contraindicated or parenteral
Labetalol fails to control BP
Preparation Withdraw 1 ampoule (20 mg) of hydralazine + 19 ml of normal saline = 20 mg/20 ml
(1 mg/ml)
Bolus dose (s) 1st dose – 5 mg (5 ml); given in 2 minutes
2nd dose – 5 mg (5 ml); given in 2 minutes if BP is 160/110 mmHg 30 minutes
after the 1st bolus
*3rd dose – 5 mg (5 ml) may be given if SBP is 180 mmHg 30 minutes after the
2nd bolus and rapid BP controlled is desired
*In hypertensive emergency (SBP 180 mmHg) or in situation where rapid BP controlled is desired,
3rd bolus dose of intravenous hydralazine may be given at the discretion of managing specialist.
42. Infusion dose IV Hydralazine
Indication BP 160/110 mmHg after 2 or 3 boluses of intravenous hydralazine
Preparation Withdraw 2 ampoules (40 mg) of hydralazine + 38 ml of normal saline = 40 mg/40 ml (1
mg/ml)
Titration Starting dose is 1 mg/H (1 ml/H)
Titration should be done at the rate of 1 mg/H (1 ml/H) every 30 minutes up to
maximum rate of 10 mg/H (10 ml/H) to achieve target BP
Target BP: 140 – 150/90 – 109 mmHg
Maintain the dose if target BP is achieved
Titrate down the dose if BP is < target BP
Hydralazine should be considered if BP is uncontrolled after infusion of IV labetalol at
maximum rate of 160 mg/H (32 ml/H)
43. Magnesium sulphate (MgSO4) – agent of choice
Associated with almost 50% risk reduction
Indications for Magnesium Sulphate:
1. Eclampsia (as treatment to control seizure)
2. In severe pre-eclampsia as defined by the following (after discussion with O&G specialist):
3. Severe hypertension associated with any of the following;
Significant proteinuria of ≥ 2+
Symptoms of impending eclampsia: headache, blurring of vision, epigastric pain, nausea or
vomiting
Complications from severe pre-eclampsia: HELLP syndrome, acute pulmonary oedema,
placenta abruption, intrauterine death
4. As fetal neuroprotection for woman whose delivery is indicated at ≤ 32 weeks
44. 1 vial MgSO4 contains 2.47g/5ml
(1g MgSO4 = 2 ml MgSO4)
Can be given intravenously or
intramuscularly
45. Loading dose Maintenance dose
Infusion pump Syringe pump
Dose 4g 1g/H 1g/H
Preparation 8ml (4g) of MgSO4 +
12 ml of NS = 20 ml
50ml (24.7g) of MgSO4 +
450ml NS
10ml (5g) of MgSO4 + 40
ml of NS
Administration Give 4g MgSO4 in
slow bolus for15 – 20
min
21ml/H (1g/H) 10ml/H (1g/H)
In cases where seizure occurs after administration of MgSO4, a further bolus of 2 – 4 g MgSO4 can be
given with close monitoring of Mg level. Serum magnesium can be taken before the repeated bolus
46. Loading dose Maintenance dose
Dose Total 10g (5g each buttock) 5g every 4 H in alternate buttock
Preparation 10ml (5g) of MgSO4 + 1 ml of local
anaesthesia = 11 ml
10ml (5g) of MgSO4 + 1 ml of local
anaesthesia = 11 ml
Administration IM injection in each buttock IM injection into alternate buttock every 4
hourly
In cases where seizure occurs after administration of MgSO4, a further bolus of 2 – 4 g MgSO4 can be
given with close monitoring of Mg level. Serum magnesium can be taken before the repeated bolus
MgSO4 if the situation allows.
47. Parameters Interval of monitoring Target
Blood Pressure 15 minutes 140 – 150/90 – 109 mmHg
Pulse rate 15 minutes 60 bpm
Respiratory rate Hourly 16 breaths per minute
Urine output Hourly 30 ml/H or 100 ml/4 hours
Deep tendon reflex of
knee
Hourly Presence of reflexes
*Monitoring of magnesium level is NOT routine in women receiving MgSO4.
However, if there is suspicion of magnesium toxicity, the Mg level should be checked
48. Loss of deep tendon (patella) reflex
Respiratory rate - <16 breaths per min
Pulse rate - <60 bpm
STOP MGSO4; CHECK MG LEVEL; MAY RESUME MGSO4 IF MG
LEVEL IS NORMAL OR REFLEXES RETURN
49. Cardiorespiratory arrest
STOP MgSO4 immediately
Resuscitation – DR ABC; intubation and ventilation
Intravenous calcium gluconate as antidote
10% Calcium Gluconate 10ml IV over 10 minutes
50. Urine output < 100 ml/4H @ < 30 ml/H
Reduced urine output is NOT a sign of MgS04
toxicity
Assessment – hydration status, serum BUSE/creat,
serum Mg level (if available)
Check reflexes and respiratory rate to ensure no
signs of toxicity
51. Urine output < 100 ml/4H @ < 30 ml/H
If serum creatinine is normal and Mg level is within therapeutic range then
continue MgSO4 at 1 g/H.
If serum creatinine is normal and Mg level is raised above therapeutic range,
reduce the dose by half to 0.5 g/H
If serum creatinine is raised or serum Mg level is above the therapeutic range then
STOP the infusion
If unable to do serum Mg level, reduce the maintenance dose to 0.5mg/H
May consider fluid challenge with 500ml NS/H after discussion with
Once urine output improves, the maintenance dose should be resumed at 1g/H
53. Definition of hypertension – persistent BP ≥ 140/90 mmHg AT LEAST 15
minutes apart; especially BP ≥ 160/110 mmHg.
Be aware of white coat hypertension, masked hypertension and transient
hypertension.
Be familiar with conditions that define preeclampsia and the severe
features of preeclampsia
Start T. Aspirin 100 – 150 mg/day; to be taken at night before 16 weeks (12
– 16 weeks); definitely before 20 weeks; T calcium lactate 1 g BD from
20 weeks onwards.
54. Start antihypertensive when BP persistently ≥ 140/90 mmHg with target
BP <160/80 – 85 mmHg
There’s urgency to reduce BP of ≥ 160/110 mmHg to non-severe
hypertension.
Be familiar with the suitable type of antihypertensives as well as the
dosage and dilution of drugs involved in the management of severe
hypertension
55. 1. NICE clinical guideline. Hypertension in pregnancy: the management of
hypertensive disorders during pregnancy. RCOG. The Royal College of
Midwives. 2011
2. Zahra Hoodbhoy. The FIGO textbook of pregnancy hypertension.
October 2016.
3. Brown et al. Hypertensive Disorders of Pregnancy: ISSHP Classification,
Diagnosis, and Management Recommendations for International
Practice. ISSHP.2018;72:24 – 43.
4. Malaysian Clinical Practice Guidelines: Management of hypertension.
5th Edition (2018)
56. 5. Rolnik et al. ASPRE trial: performance of screening for preterm
preeclampsia. Ultrasound Obstet Gynaecol 2017;50:492 – 495.
6. Rolnik et al. Aspirin versus Placebo in Pregnancies at High Risk for
Preterm Preeclampsia. N Engl J Med 2017;377:613 – 22.
7. Magee et al. Less-Tight versus Tight Control of Hypertension in
Pregnancy. N Engl J Med 2015;372:407 – 17.